DIA MedTech Conclave - 2025

MedTech Next:
Innovate, Regulate, Elevate

10-11 October 2025
Welcomhotel by ITC Hotels, Gurgaon-Delhi Expressway, **New Delhi,** India

For the first time, presenting The DIA MedTech Conclave 2025, specially designed program in medical devices, from the house of DIA. This program intends to be an august gathering of torchbearers of the medical device industry in India leading it to the global. Leaders, regulatory experts, healthcare professionals and focused specialists who are contributing their every bit in advancing medical technology. This is a perfect blend of learning and contribution for all, with well-crafted content, thoughtfully designed interactive sessions, participating opportunities and experience centers for trying solutions and platforms of your choice hands-on. The session envisages taking a walk-through leading trends, evolving regulations, discussion about compelling best practices and journey through the leaders. It will cover medical devices, in vitro diagnostics, combination products, and software medical devices including artificial intelligence. The Conclave will be a two-days dedicated extensive session with regulatory affairs, quality system, clinical evidence and risk management practices, and post-market surveillance frameworks.

With a focused single-track format for maximum engagement, the event will feature multiple sessions and discussions on key challenges and opportunities in 3D *(Devices, Diagnostics, and Digital).* Attendees will *gain actionable insights on regulatory compliance, design validation, patient safety, and global market access,* shaping the future of MedTech innovation.

This conclave offers an excellent networking *opportunity* with industry pioneers, regulators, start-ups, and academia, fostering collaboration and driving excellence in the MedTech ecosystem.

WHAT TO EXPECT

Learning Objectives

DIA MedTech Conclave 2025 is designed to provide participants with in-depth knowledge and practical insights into the evolving MedTech landscape. By attending, participants will:

- **Understand Global & Indian Regulatory Pathways** – Navigate marketing authorization and compliance for medical devices, IVDs, and combination products.
- **Master Quality System & Risk Management** – Learn best practices for design validation, verification, and conformity assessment.
- **Explore AI & SaMD Regulations** – Gain insights into compliance, standards, and evaluation of Software as a Medical Device in EU and US.
- **Strengthen Clinical & Post-Market Strategies** – Enhance knowledge of clinical evaluation, post-marketing surveillance, and materiovigilance.
- **Network & Collaborate** – Connect with regulators, industry leaders, start-ups, and academia to drive MedTech innovation.

This conclave is a must-attend for professionals in regulatory affairs, quality, clinical research, and MedTech development aiming for global excellence.

Featured Topics

DIA MedTech Conclave 2025 will cover key areas shaping the future of medical devices, in vitro diagnostics, combination products, and Software as a Medical Device (SaMD). The sessions will provide expert insights, regulatory updates, and best practices across the MedTech ecosystem.

- **Regulatory Pathways for Market Authorization** – India & global requirements for medical devices and diagnostics.
- **Quality & Risk Management** – Design validation vs. verification, conformity assessment, and compliance strategies.
- **Fundamentals and Emerging Regulatory Perspectives in AI and Software as Medical Device** – Decoding the EU vs US requirements.
- **Why are emerging cybersecurity trends and updates in medical devices so important** (Software as Medical Device & AI in MedTech)?
- **Regulatory & Clinical Considerations for SaMD** – Standards, compliance & evaluation of Software as a Medical Device.
- **Clinical Evaluation & Evidence Generation** – Strategies for regulatory submissions and market access.
- **Risk Management for Medical Devices** – Implementation of ISO 14971 and best practices.
- **Safety & Post-Market Surveillance** – Materiovigilance, complaint management, and post-marketing clinical follow-up.
- **Challenges and Opportunities for Indian MedTech Companies** while going global.

This conclave provides a comprehensive learning experience, addressing critical aspects of MedTech innovation, regulation, and patient safety.

Who Should Attend

The **DIA MedTech Conclave 2025** is designed for professionals involved in the development, testing, regulation, and commercialization of medical devices, in vitro diagnostics, combination products, and Software as a Medical Device (SaMD).

- **R&D and Product Development Teams** – Understand the latest trends in MedTech innovation and regulatory expectations
- **Regulatory Affairs & Compliance Professionals** – Stay updated on evolving global and Indian regulatory requirements and effectively implement key updates and actionable items
- **Quality Assurance & Risk Management Experts** – Learn best practices in QMS, design validation, and conformity assessment.
- **Clinical Research & Medical Affairs Professionals** – Gain insights into clinical evaluation, post-market surveillance, and materiovigilance.
- **Healthcare & Policy Experts** – Engage in discussions on safety, compliance, and market access.
- **Start-ups & Entrepreneurs** – Connect with industry leaders and explore pathways to global markets.

This conclave offers a unique opportunity for networking, learning, and collaboration, making it essential for stakeholders shaping the future of MedTech.

PROGRAM COMMITTEE

Dr Ashish Indani
Program Chair
General Manager – Clinical and Medical Affairs, Advance MedTech Solutions (AMS), Mumbai / Vadodara

Dr Srirupa Das
Healthcare Industry Leader, Independent, Mumbai

Dr Priyadarshini Arambam
Director, Clicebo Solutions Pvt Ltd, New Delhi

Sundeep Agarwal
Sr. Vice President, Regulatory Affairs & Quality Assurance, Remidio, Delhi/Bengaluru

SESSION CHAIRS

Omprakash Sadhwani
Director XPLORE Healthcare Solutions LLP. Ex-Joint Commissioner (HQ) and Drugs Controller, Maharashtra Food and Drug Administration.

Rajendran Varadharaj
General Manager Operations - MHS, TUV SUD India

AGENDA: Day 1, 10 October 2025; Friday	
8:00-9:00AM	**Registration and Welcome Coffee**
9:00-9:05 AM	**Welcome Remarks from DIA:** [5 min] **Dr Ashok Swain**, General Manager – DIA India - Welcome the audience, house rules, and introduce Program Chair
9:05- 9:15 AM	**U.S. FDA Welcome Remarks** **Mr. Gregory Smith,** Director, FDA India Office [10 mins]
9:15 – 9:30 am	**Meeting Opening Remarks by Program Chair:** [15 min] **Dr Ashish Indani**, General Manager & Head – Clinical and Medical Affairs, AMS
9:30-11:00AM	**D1.S1: Advancing MedTech in India: A Roadmap for Scalable Impact** Session Chair: **Dr Srirupa Das**,Healthcare Industry Leader, Mumbai Session Overview: The Opening Session sets the stage for a dynamic exploration of how technology, AI, and MedTech start-ups are revolutionizing healthcare delivery and access. It will spotlight emerging innovations, highlight India's growing MedTech ecosystem, and bring together thought leaders in a panel discussion to chart a collaborative roadmap for advancing medical technology. Join us to uncover how these forces are shaping the future of healthcare in India and beyond.
9:30-10:00 AM	**D1.S1.T1: Tech and AI – Transforming and Democratizing Healthcare** **Dr Moni Abraham Kuriakose**, Co-Founder, Medical Director and CEO Kerala Operations, Karkinos Healthcare
10:00 -10:30AM	**D1.S1.T2: Role of MedTech Start-up Ecosystem in Healthcare Transformation** **Prof. (Dr) Sucheta Banerjee Kurundkar**, Director Research, KLE Academy of Higher Education & Research
10:30-11:00AM	**D1.S1.T3: Panel Discussion: Advancing Medical Technology in India – Way forward** Moderator: **Dr Srirupa Das,** Healthcare Industry Leader, Mumbai Panelist: Speakers with the additional presence of 3. **Prof. Dinesh Kalyansundaram**, CBME- IIT Delhi, Principal Investigator at mPragati at IIT Delhi. 4. **Goutam Bhattacharya**, CEO, Life Sciences Sectors Skill development Council 5. **Kamal Shahani,** Managing Director- Cliniminds; Founder & Managing Director - Tenet Health Edutech.
11:00-11:30AM	Tea / Coffee & Networking Break
11:30-1:00PM	**D1.S2: Regulatory requirements for Marketing Authorization from Design to Commercial - India and Global Perspective** Session Chair: **Sundeep Agarwal**, Senior Vice President – Regulatory Affairs & Quality Assurance, Remidio Innovative Solutions Pvt. Ltd. Session Overview: This session provides critical insight into the complex regulatory pathways shaping the global MedTech sector. In India, CDSCO regulates devices under the Medical Devices Rules, 2017, enforcing a risk-based classification (Class A–D), mandatory licensing, ISO 13485-compliant quality systems, and adherence to ISO 10993 biocompatibility standards. Recent updates, including the April 2025 FAQs, emphasize clearer documentation protocols, clinical evidence requirements, and vigilance mechanisms. Globally, the rise of digital health technologies, including Software as a Medical Device (SaMD) and AI, adds complexity. Internationally, regulatory frameworks are becoming more rigorous and harmonized. The EU MDR imposes comprehensive clinical evaluation, Unique Device Identification (UDI),

	and lifecycle-based post-market surveillance. The U.S. FDA's Center for Devices and Radiological Health (CDRH) and Digital Health Center of Excellence supports innovation through programs like the Breakthrough Devices Program and, yet demands robust premarket submissions, cybersecurity controls, transparency, adaptive AI, continuous learning models and real-world evidence, especially for Software as a Medical Device (SaMD). For industry professionals, proactive regulatory alignment from design through commercialization is essential to mitigate compliance risk. For investors, a strong digital health regulatory strategy enhances market readiness, supports scalable growth, and de-risks capital deployment in a competitive, innovation-driven sector.
11:30-11:50AM	**D1.S2.T1: Building a Future-Ready Regulatory Ecosystem - CDSCO's Role in India's MedTech Growth and Global alignment** **Aseem Sahu,** DDC, CDSCO, India *(invited)*
11:50-12:10 PM	**D1.S2.T2: Navigating Regulatory Pathways for Software and Artificial Intelligence Medical Devices under the EU Medical Device Regulation (MDR) vs US FDA vs Indian MDR** **Sundeep Agarwal,** Senior VP – RA& QA, Remidio Innovative Solutions Pvt. Ltd
12:10 – 1:00 PM	**D1.S2.T3: Panel Discussion: Accelerating Innovation While Managing Risk: Global Regulatory Trends in MedTech"** Moderator: **Sudhakar Mairpady,** Director, Regulatory Affairs & Government Affairs, BD Panelists: Speakers with the additional panelists 3. **Prof. (Dr) Sucheta Banerjee Kurundkar**, Director Research, KLE Academy of Higher Education & Research 4. **Anil Chaudhari,** Founder and CEO, Operon Strategist
1:00-2:00PM	**Lunch Break**
2:00-3:30PM	**D1.S3: QMS in Medical Device Development: Design & Development, Verification & Validation, and Compliance Requirement in India, US & EU** Session Chair: **Rajendran Varadharaj,** General Manager Operations - MHS, TUV SUD India Session Overview: This session will provide a comprehensive overview of Quality Management System (QMS) requirements across major regulatory jurisdictions including an emphasis on evolving demands in digital health and AI-enabled medical technologies Focusing on ISO 13485 as the global benchmark, the session will explore region-specific expectations, including India's Medical Devices Rules (2017), the U.S. FDA's proposed Quality Management System Regulation (QMSR), and the EU MDR's emphasis on lifecycle-based quality assurance. Key topics include design and development controls, verification and validation (V&V), documentation practices, and risk management. Verification and validation (V&V) ensure that a medical device is designed correctly (verification) and performs safely and effectively for its intended use (validation). This is critical for regulatory approval, patient safety, and product reliability. Attendees will gain actionable insights on aligning QMS strategies to support compliance, product integrity, and timely market access. This session is ideal for regulatory, quality, and R&D professionals seeking to navigate evolving global standards while driving innovation in medical device development.
2:00-2:20PM	**D1.S3.T1: Redefining Quality: FDA's Alignment with ISO 13485 and Its Impact on Manufacturers** **Rupam Chaudhury,** GLOBAL HEAD – Lifesciences and Healthcare Engineering, TCS
2:20-2:40PM	**D1.S3.T2: When Quality is the Key – Quality Management Systems, Conformity Assessment, and Compliance Strategies for Medical Devices.** **Vareena Raina**, Advisor/Trainer for Medical device QMS and regulatory requirements, Bhat Assurance International (BAI)
2:40-3:30PM	**D1.S3.T3: Panel Discussion with Q&A:** Moderator: **Rajendran Varadharaj,** General Manager Operations - MHS, TUV SUD India Panelists: Speakers with the additional panelists

3. **Leena Bera,** CEO, Zenith

4. **Kulveen Singh Bali,** Director - Regulatory and Quality, Philips

3:30-4:00PM	**Tea/Coffee & Networking Break**
4:00-5:30PM	**D1.S4: Regulatory, Clinical and Cybersecurity Considerations for Software as a Medical Device (SaMD): Standards, AI Integration, Compliance, and Evaluation** Session Chair: **Sundeep Agarwal,** Senior Vice President – Regulatory Affairs & Quality Assurance, Remidio Innovative Solutions Pvt. Ltd. Session Overview: The emergence of Software as a Medical Device (SaMD) introduces complex regulatory, clinical, and cybersecurity challenges requiring coordinated, multidisciplinary solutions. This session will delve into key aspects of SaMD development and oversight, with a focus on evolving global standards, artificial intelligence (AI) integration, and compliance strategies. Discussions will include international regulatory alignment efforts, regional implementation nuances, and the implications of AI on clinical validation, transparency, and bias mitigation. With health data at the core of SaMD functionality, the session will also address cybersecurity as a critical pillar—covering threat landscapes, data protection measures, risk management frameworks, and post-market surveillance mechanisms. By examining the entire lifecycle of SaMD, from design through deployment and monitoring, this session aims to equip participants with a robust understanding of current best practices, regulatory expectations, and evaluation methodologies. Attendees will leave with actionable insights into ensuring the safety, efficacy, and security of SaMD in real-world clinical settings.
4:00-4:20PM	**D1.S4.T1: Navigating the future: Trends and Strategic path for Healthcare AI Regulation in the APAC region**
4:20-4:40PM	**D1.S4.T2: Connected, But Protected? Navigating the New Cybersecurity Mandates in MedTech** **Srinivasa Reddy,** Sr. VP - Operations, Regulatory and Govt. Affairs, SS Innovations International Inc.
4:40-5:00PM	**D1.S4.T3: Designing for success: aligning QMS for SaMD and AI product development in MedTech** **Sreejith Viswam,** Director- Quality and Regulatory, Stryker Global Technology Centre and APAC NPD, Stryker
5:00-5:30PM	**D1.S4.T4: Panel Discussion: Global Standards, Local Realities: Aligning SaMD & AI Development, Clinical Application with Evolving Regulations** Moderator: **Sundeep Agarwal,** Senior VP – RA& QA, Remidio Innovative Solutions Pvt. Ltd. Panelists: Speakers
5:30 – 6:00 PM	**D1.S4a: FDA Center for Devices and Radiological Health (CDRH) Fundamentals: Regulatory Pathways, Resources, and Innovation** **Stephanie Shedd,** Biomedical Engineer, International Policy Analyst, FDA CDRH
6:00-6:15 PM	**Day End / Wrap Up**

AGENDA: Day 2, 11 October 2025; Saturday	
9:00-9:10 AM	**Welcome to Day 2 – DIA** [5 min] **Recap of Day1 & Day 2 Opening Remarks by Program Committee Co-Chair** [10 min]
09:10 – 9:30 am	**D2.KNA.1. Keynote Address: Age of wearables - How widely are they deployable to enhance clinical conformity.** **C. Palani Palaniappan, Ph.D**, CEO, Aridica Corporation, USA. **DIA Global Board of Directors**
9:30-11:00AM	**D2.S5: Bridging the Gap: Globalizing Indian MedTech through Policy, Partnership, and Purpose** Session Chair: **Mr. Omprakash Sadhwani,** Director, XPLORE Healthcare Solutions LLP. Ex-Joint Commissioner (HQ) and Drugs Controller, Maharashtra Food and Drug Administration**,** India Session Overview: The Day 2 Opening Session explores India's journey towards global MedTech leadership, focusing on policy, partnerships, and purposeful innovation. Industry leaders will share insights on overcoming globalization challenges, seizing emerging opportunities, and scaling innovations. A high-impact panel will delve into the collaborative potential of the Medical Device Policy 2023, highlighting the role of regulatory agencies and industry in shaping a globally competitive Indian MedTech ecosystem.
9:30-10:00AM	**D2.S5.T1: Breaking the Barriers to Breakthrough– Challenges and Opportunities for Indian MedTech companies in their globalization**
10:00-10:30AM	**D2.S5.T2: A MedTech Business Leaders's Insights** **Chander Shekhar Sibal**, CEO, SS Innovations Private Limited, Gurgaon
10:20-11:00AM	**D2.S5.T3: Panel Discussion: Title: Collaborating between agencies and industry – the spotlight of Medical Device Policy 2023.** Moderator: **Omprakash Sadhwani** Panelists: Speakers with the additional presence of 3. **Rajiv Nath,** Managing Director - Hindustan Syringes & Medical Device Ltd. Forum Coordinator, Association of Indian Medical Device Industry (AIMED) 4. **Pavan Choudary,** Chairman, Medical Technology Association of India (MTaI) 5. **Dr Rajiv Chhiber,** Vice President, External Affairs (Policy, Govt Relations & Outreach), Sahajanand Medical Technologies; FICCI representative. 6. **Dr Ravi Rathod**, General Manager- Policy and Strategic Affairs (Regulatory), Innvolution Healthcare Pvt. Ltd. Advisor-Health to PHD Chamber of Commerce and Industry
11:00-11:30AM	**Tea/Coffee & Networking Break**
11:30-1:00PM	**D2.S6: Clinical Evidence for Medical Devices** Session Chair(s): **Priyadarshini Arambam,** Director, Clicebo Solutions Pvt Ltd, New Delhi Session Overview: Clinical Evaluation is a critical area of medical devices. Not only the regulators, but other stakeholders such as reimbursement authorities, insurers and payers also ask for the clinical evidence. It is indeed the most critical aspect for the clinicians to get the confidence and reason for use of medical devices. However, with the changing landscape of regulation, clinical practices and their synergies, the clinical evidence also has significant adoptions. This session focuses on these synergies and adoptions.
11:30-11:50AM	**D2.S6.T1: Clinical Evaluation: Current guidelines and how it should be done? Who needs what for regulatory submissions and market access- EU, India & Global.** **Aaditya Vats,** Director - Regulatory Affairs and Quality Assurance, Terumo India Private Limited
11:50-12:20PM	**D2.S6.T2: Realistic clinical evidence for medical devices – What, When, How much?** **Dr Ashish Indani**, General Manager & Head – Clinical and Medical Affairs, AMS

12:20-1:00PM	**D2.S6.T3: Panel Discussion: Clinical Evidence beyond Regulatory Requirements** Moderator: **Dr Priyadarshini Arambam**, Director, Clicebo Solutions Pvt Ltd, New Delhi Panelists: Speakers with the additional panelists **3. Dr. Rajlakshmi Borthakur**, CEO & Founder, TerraBlue XT.
1:00-2:00PM	**Lunch Break**
2:00-3:30PM	**D2.S7: Risk Management for Medical devices** Session Chair: **Dr Ashish Indani,** General Manager – Clinical and Medical Affairs, Advance MedTech Solutions (AMS) Session Overview: Risk Management is the most critical function in medical device lifecycle management. While there are several set guidelines in Medical Devices including ISO 14971, the width of diversity of devices compels use high level of discretionary efforts, deliberation and carefully individualized approach for each device. This requires critical intersecting expertise in Medical Devices, understanding of clinical use and human factors, thorough knowledge of Risk Management, and systematic approach of evidence-based compliances.
2:00-2:20PM	**D2.S7.T1: Managing Risks or Risk Management? - A holistic approach to ensure that device risks are realistic and not realized.** **Sushmita Roy Chowdhury**, General Manager Regulatory Affairs, Romsons Groups Pvt. Ltd.
2:20-2:40PM	**D2.S7.T2: Risk Communication: Pathway from Risk management to Labelling** **Kalindi Hapani,** Senior Manager - Medical Safety & Device Safety, COD Research
2:40-3:30PM	**D2.S7.T3: Panel Discussion: Accelerating Innovation While Managing Risk: Global Regulatory Trends in MedTech** Moderator: **Dr Ashish Indani,** Advance MedTech Solutions (AMS) Panelists: Speakers with the additional panelists 3. **Preety Sharma**, Head - Regulatory Affairs, Edwards Lifesciences 4. **Dr Manoj Karwa**, Head of Clinical Trials & Pharmacovigilance, Auriga Research.
3:30-4:00PM	**Tea/Coffee & Networking Break**
4:00-5:30PM	**D2.S8: Post-marketing surveillance to ensure product safety** Session Chair **Dr Srirupa Das,** Healthcare Industry Leader, Independent Session Overview: Continuing safety assessment across the product life cycle is imperative to ensuring patient safety and welfare of the India population. This section delves into the current state of post-marketing safety surveillance of medical devices; and deliberates on how multisector collaboration can enhance the same.
4:00-4:20PM	**D2.S8.T1: India's Experience with MvPI – Current State of Adverse Event Reporting of Medical Devices** **Dr Shatrunjay Shukla,** Assistant Scientist, Indian Pharmacopoeia Commission, MoH & GFW, GoI
4:20-4:40PM	**D2.S8.T2: Post marketing safety surveillance – current practices and challenges** **Vidhya G G**, Lead Materiovigilance– Clinical Affairs, Helathium
4:40-5:30PM	**D2.S8.T3: Panel Discussion: Transformational strategies for enhancing post-marketing safety surveillance** Moderator: **Dr Srirupa Das**

	Panelists: Speakers with the additional panelists 3. **Dr Bishnu Panigrahi**, Group Head - Medical Strategy and Operations, Fortis Healthcare. 4. **Dr Ravi Rathod**, General Manager- Policy and Strategic Affairs (Regulatory), Innvolution Healthcare Pvt. Ltd. Advisor-Health to PHD Chamber of Commerce and Industry
5:30-5:45PM	**Closing Remarks & Vote of Thanks**

PAYMENT INFORMATION

Meeting registration for an individual participant with **ONLINE payment** can be completed directly through the DIA website.

For **DIA MedTech Conclave 2025**: Register Online

For group registrations, please contact the meeting manager (below table).

BANK ACCOUNT details for other modes of payment:

Account Name: DIA (INDIA) PRIVATE LIMITED
Account No: 061010200024611
Bank Name: AXIS BANK LIMITED
Branch Name: Dhiraj Baug, Near Hari Niwas Circle,
LBS Marg, Thane (W) – 400602
IFSC Code: UTIB0000061 MICR Code: 400211013
Swift Code: AXISINBB061

Add Membership for Instant Disocunts

Join DIA today to enjoy discounted meeting registration fees and unlock all membership benefits. Visit www.diahome.org and select the "Membership" option under the "Get Involved" tab for more details.
Select the **'Add Membership'** option during registration to instantly avail membership discount on the registrations fee.

CHEQUE / DRAFT

Completed form, along with draft/cheque made payable to DIA (India) Private Limited should be sent to:
Vinita Shetty | Finance Manager
DIA (India) Pvt. Ltd.
Cowork30, Office #201, ACME Plaza-2, Chakala
Andheri- Kurla Road, Andheri (East), Mumbai – 400059

Email: vinita.shetty@diaglobal.org. Cell: +91 9769764645

PRIVACY POLICY

DIA respects the privacy of all its members and customers. To view our policy, click the link below: https://www.diaglobal.org/en/about-us/privacy-policy. You agree that your personal data will be transferred to DIA in the US.

*Academia Category

The ACADEMIA category applies to individuals with primary, full-time affiliation to a bona fide academic institution, and includes STUDENTS. Proof of appointment or enrollment is required.

REGISTRATION FEES: DIA MedTech Conclave - 2025

Category	Early Bird Rate (Up to 10 Aug)	Advance Rate (11 Aug – 09 Sep)	Standard Rate (from 10th Sep)
Industry – Member	INR 6,000 + GST	INR 9,000 + GST	INR 10,500 + GST
Industry – Non-member	INR 10,500 + GST	INR 13,500 + GST	INR 15,000 + GST
Academia*/ Non-Profit / Govt – Member	INR 5,250 + GST	**DIA membership Discounts:** 71% off for students (₹ 1,970 + GST) 50% off for academia/government (₹ 3,397 + GST)	
Academia*/ Non-Profit / Govt – Non-member	INR 9,750 + GST		

For Group Registrations: Please contact meeting manager. Email: nishank.nivedit@diaglobal.org | Mob: +91 8178837734

DIA Cancellation & Refund Policy :

1. **Cancellation Deadline**: Cancellations must be submitted in writing and received by 60 days before the meeting to qualify for a refund. Cancellations received after this date will not be eligible for any refund.
2. **Transfer Policies:** Registrations may be transferred to a colleague at any time, but membership benefits are non-transferable. Please notify the DIA India office in writing. Substitute registrants will be charged any applicable non-member fees at the rate in effect on the transfer date.
3. **No-Shows and Late Cancellations**: Registrants who do not cancel in writing by the deadline and do not attend the event will remain liable for the full registration fee. No refunds will be issued under such circumstances.
4. **Administrative Fee:** A 25% administrative fee will be deducted from all eligible refunds.
5. **Force Majeure:** DIA reserves the right to alter the venue or the date. In the event of cancellation or postponement due to circumstances beyond DIA's control (including but not limited to natural disasters, public health emergencies, government restrictions, or strikes), DIA shall not be held liable for any resulting costs or damages, and refunds may be partially or fully waived at DIA's discretion.
6. **Travel and Accommodation Liability:** DIA is not responsible for any airfare, hotel, or travel-related expenses incurred by participants. These arrangements are the sole responsibility of the registrant.
7. **Refund Processing and Currency Disclaimer:** Eligible refunds will be processed within 60 business days after the conclusion of the event. Refunds will be made in the original transaction currency, and DIA will not be liable for any bank charges or currency fluctuations.

DIA REGISTRATION FORM

PLEASE PRINT ALL INFORMATION CLEARLY

Dd Month 2025

Please check the applicable **category:** ☐ Industry ☐ Government ☐ Academia ☐ Student

Last Name | **First Name** | **Middle Initial** | **Please check one:** ☐ Mr. ☐ Ms. ☐ Dr. ☐ Prof.

Job Position | **Name of Organization (Primary Affiliation)**

Address: (As per your country's format)) | City | Postal Code | Country | ☐ Home ☐ Business

Mobile Number (Required) | Telephone Number

Email (Required for confirmation)

If sending this form by post or courier, please provide a copy of the registrant's business card.